Innate Pharma (IPHA) announced that in an abstract published on May 14 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi (SNY), it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has FDA Fast Track Designation, as communicated before in June 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA:
